This is a working overview of regulatory status, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-15. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
===== Break ===== "The Bolivarian Republic of Venezuela has decided, in the full exercise of its sovereignty, to break diplomatic relations with the Republic of Paraguay and to proceed with the immediate withdrawal of its diplomatic personnel accredited in that country".- Statement by the Venezuelan executive (c. January 2025). Venezuela broke diplomatic relations with Paraguay on 6 January 2025 due to Santiago Peña's recognition of Edmundo González Urrutia as the winner of the election in Venezuela. Caracas considered this interference in its internal affairs and withdrew its diplomatic personnel from Asunción. In response, the Paraguayan government reaffirmed its support for González Urrutia and demanded the departure of the Venezuelan ambassador and his team within 48 hours.
=== I: Diseases of the circulatory system === (I25.4) Coronary arteriovenous fistula, acquired (I28.0) Arteriovenous fistula of pulmonary vessels Pulmonary arteriovenous fistula: between an artery and vein of the lungs, resulting in shunting of blood. This results in improperly oxygenated blood. (I67.1) Cerebral arteriovenous fistula, acquired (I77.0) Arteriovenous fistula, acquired (I77.2) Fistula of artery
== Background == The match was a repeat of the 1973 final, making it the fourth repeated final pairing. Ajax won the 1973 final 1–0. Ajax was defending the title, having won in 1995 when they defeated Milan 1–0. Juventus had not featured in the Champions League for nine years until this edition of the tournament. Juventus reached their fourth final. In the semi-finals, Juventus eliminated French side Nantes, with a 2-0 victory in the first leg at home, and 3–2 defeat in the return leg. Previously Juventus won the final in 1985, and lost in 1973 and 1983. Ajax reached their sixth final. In the semi-finals, Ajax eliminated Greek side Panathinaikos; they lost the first leg 1–0 at home, but won 3–0 in the second leg. Previously Ajax won the finals in 1971, 1972, 1973 and 1995, and lost in 1969. Juventus entered the final as 1995–96 Serie A runners-up to Milan, as well as 1995 Supercoppa Italiana winners. Ajax entered the final as 1995–96 Eredivisie champions, 1995 Dutch Supercup winners, 1995 UEFA Super Cup and 1995 Intercontinental Cup winners.
Sources: en.wikipedia.org
=== Atmosphere of Mars === In 2013, OH near-infrared spectra were observed in the night glow in the polar winter atmosphere of Mars by use of the Compact Reconnaissance Imaging Spectrometer for Mars (CRISM).
== Pharmacokinetics and pharmacogenetics == It is bioactivated hepatically to its primary metabolite, N-desethylamodiaquine, by the cytochrome p450 enzyme CYP2C8. Among amodiaquine users, several rare but serious side effects have been reported and linked to variants in the CYP2C8 alleles. CYP2C8*1 is characterized as the wild-type allele, which shows an acceptable safety profile, while CYP2C8*2, *3 and *4 all show a range of "poor metabolizer" phenotypes. People who are poor metabolizers of amodiaquine display lower treatment efficacy against malaria, as well as increased toxicity. Several studies have been conducted to determine the prevalence of CYP2C8 alleles amongst malaria patients in East Africa, and have tentatively shown the variant alleles have significant prevalence in that population. About 3.6% of the population studied showed high risk for a poor reaction to or reduced treatment outcomes when treated with amodiaquine. This information is useful in developing programs of pharmacovigilance in East Africa, and have important clinical considerations for prescribing antimalarial medications in regions with high CYP2C8 variant frequency.
=== Biosimilar drugs === Biosimilar drugs are biological products that are highly similar to an already approved biologic drug, with few or no clinically meaningful differences in terms of safety, purity, and potency. These drugs are developed to be equivalent to the reference biologic, often at a lower cost, providing alternative treatment options. In the context of ankylosing spondylitis, biosimilars are typically used as alternatives to the original biologic drugs. Biosimilars for ankylosing spondylitis may include versions of tumor necrosis factor inhibitors or other biologics commonly used in the treatment of the condition. When possible, physicians are recommended to use the original drugs over the biosimilar versions. Even biosimilars with perfect replication of the quality, composition, and other properties of the original drug are susceptible to nocebo effects.
There are mainly two methods for loading samples onto FD emitters: the emitter-dipping technique and the syringe technique. Emitter-dipping technique is simple and commonly used in most laboratories. In this technique, the solid samples are dissolved or suspended in a suitable medium, and then an activated emitter (usually a tungsten wire with many microneedles) is dipped into the solution and drawn out again. When the wire is removed from the solution, the solution of a volume about 10−2 μL adheres to the microneedles (an average length of 30 μm) or remains between them. The other technique, syringe technique, applies to the compounds which are less concentrated than 10−5 M. A droplet of the solution from a microsyringe which is fitted to a micromanipulator is deposited uniformly on the microneedles. After evaporation of the solvent, the procedure for the two techniques can be repeated several times to load more samples. The syringe technique has the advantage that measured volumes of the solution can be accurately dispensed on the center of the wire.
Sources: en.wikipedia.org
In organic chemistry, an active ester is an ester functional group that is highly susceptible toward nucleophilic attack. Activation can be imparted by modifications of the acyl or the alkoxy components of a normal ester, say ethyl acetate. Typical modifications call for electronegative substituents. Active esters are employed in both synthetic and biological chemistry. Active esters are mainly used as acylating agents. They undergo the same reactions as their unactivated analogues but do so more rapidly. They are prone to hydrolysis, for example. Of great interest is the enhanced reactivity of active esters toward amines to give amides. Active esters are prominent in biochemistry. Glutamine synthetase is an enzyme that forms an active ester from the terminal carboxylate of glutamic acid. This activation, imparted by phosphorylation, facilitates the conversion of the carboxylate to an amide called glutamine.
Folic acid, which is the synthetic form of the vitamin folate, is critical both in pre- and peri-conception. Deficiencies in folic acid may cause neural tube defects (NTDs). Women who had 0.4 mg of folic acid in their systems due to supplementing 3 months before childbirth significantly reduced the risk of NTDs. More than 80 countries use fortification of certain foods with folic acid as a measure to decrease the rate of NTDs.
Direct-to-consumer blood testing (DTC blood testing), also known as direct access testing (DAT), is a form of laboratory testing that allows consumers to order blood tests directly from a clinical laboratory without requiring a prescription or referral from a physician. This market has grown significantly in recent years, driven by consumer interest in personalized health management, advances in laboratory technology, and regulatory changes that have expanded access in many jurisdictions. These services typically offer comprehensive metabolic panels, lipid profiles, hormone testing, nutritional markers, and increasingly sophisticated biomarker assessments that were traditionally only available through healthcare providers. Over the last decade, a paradigm shift has taken place with consumers seeking greater involvement in decisions affecting their healthcare and with policies that enable this involvement.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.